Mineralys Therapeutics (MLYS) EPS (Weighted Average and Diluted) (2022 - 2026)
Mineralys Therapeutics' (MLYS) quarterly EPS (Weighted Average and Diluted) came in at -$0.47 in Q1 2026, up 40.51% year-on-year from -$0.33 in Q1 2025, and down 34.29% quarter-over-quarter from -$0.35 in Q4 2025.
Mineralys Therapeutics (MLYS) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has disclosed EPS (Weighted Average and Diluted) across 5 years of filings, most recently posting -$0.47 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.47, up 40.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 (up 46.38% YoY), and the FY2025 annual result was -$2.29, up 37.43% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.47 for Q1 2026 at Mineralys Therapeutics, down from -$0.35 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.31 in Q2 2023 to a low of -$1.75 in Q4 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.7 (2024), against an average of -$0.84.
- Across the five-year window, EPS (Weighted Average and Diluted) surged 75.4% in 2023 and plunged 167.74% in 2024, its largest moves.
- Mineralys Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.75 in 2022, then surged by 64.0% to -$0.63 in 2023, then tumbled by 55.56% to -$0.98 in 2024, then surged by 64.29% to -$0.35 in 2025, then plunged by 34.29% to -$0.47 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.47 (Q1 2026), -$0.35 (Q4 2025), and -$0.52 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Mineralys Therapeutics | 1.95 Bn | 1.95 Bn | - | -0.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.47 |
| Dec 31, 2025 | -0.35 |
| Sep 30, 2025 | -0.52 |
| Jun 30, 2025 | -0.66 |
| Mar 31, 2025 | -0.79 |
| Dec 31, 2024 | -0.98 |
| Sep 30, 2024 | -1.13 |
| Jun 30, 2024 | -0.83 |
| Mar 31, 2024 | -0.70 |
| Dec 31, 2023 | -0.63 |
| Sep 30, 2023 | -0.57 |
| Jun 30, 2023 | -0.31 |
| Mar 31, 2023 | -0.51 |
| Dec 31, 2022 | -1.75 |
| Sep 30, 2022 | -1.29 |
| Jun 30, 2022 | -1.26 |
| Mar 31, 2022 | -1.48 |